Key Takeaways
- Margin hit from COVID inventory, guidance intact: Reported EBITDA margin of 22.3% absorbed a one-time COVID inventory charge; adjusted margin was ~24%, and full-year guidance of 21–22% is reaffirmed.
- US business resets to a higher base: Lenalidomide launch and Lanreotide share gains drove US sales to $179 mn; management now calls the $175–180 mn range a sustainable new base, barring a dramatic reversal.
- One India engine firing on all cylinders: Core portfolio ex-COVID grew 15% YoY, with branded prescriptions, trade generics, and consumer health all delivering double-digit growth on strong volume and new launches.
- Pipeline catalysts are stacked for H2 and beyond: Generic Advair is on track for H2 FY23 launch, Leuprolide is imminent, and peptide launches begin in H1 FY24, building a multi-year complex-generic story.
- What to watch next quarter: Goa plant resolution and its impact on Abraxane timing, the pace of Lanreotide share gains toward the 15% target, and whether the US base holds at the new guided level.
US Generics: The Base Reset and Pipeline
- Lenalidomide launch delivered the step-change: The quarter’s launch, combined with steady Lanreotide market share growth from 4.6% to 9.6%, pushed core US formulations sales to $179 mn, a 25% YoY jump.
- Management calls a new floor: The $175–180 mn level is now characterized as a sustainable base for the business, with Lenalidomide repeatability expected at least through this fiscal year. Base business erosion is described as “nothing untoward,” with new launches offsetting the normal quarterly decline.
- Lanreotide share march continues: Market share reached 9.6% in Q2, tracking toward the earlier guidance of roughly 15% by year-end. The existing Lanreotide infrastructure is expected to support the imminent Leuprolide Depo launch, which will ramp slowly along a similar trajectory.
- Advair timing holds, competition looks limited: Management is sticking to its H2 FY23 launch guide, pending FDA review of responses to questions. Only one subsequent filer is known, so limited competition is expected for at least two years, and Cipla believes its cost position is “fairly superior,” as it was for Albuterol.
- Growth will moderate as scale builds: Management acknowledged that as the US base becomes larger, growth rates will not stay as high as in the past; pipeline choices in respiratory and peptides will remain distinctive, but the trajectory will moderate after 2–3 years.
Umang Vohra: “I think this current level of our business at 175 to 180, unless there is something that goes dramatically wrong. I think you could translate this to seeing this as a new base for the business.”
One India: Broad-Based Volume and Reach
- Core portfolio grew 15% ex-COVID: Branded prescription business posted double-digit growth across therapies, driven by a healthy mix of price, volume, and new launches. Eight new brands were launched in Cardiology, Diabetes, Urology, Gynecology, and Respiratory during the quarter.
- Trade generics penetrate deeper: The franchise delivered double-digit growth over last year, with steady order flow from tier-2 to tier-6 towns where growth outpaces metros and tier-1 cities. Ten new products were launched in key therapies within the generics franchise.
- Consumer health transfers are working: Brands transferred into the consumer division are tracking at 14% growth momentum, and the overall consumer business is delivering over 20% growth versus last year. Products with strong customer equity in the trade generics portfolio are being evaluated for future transfer.
- Therapy-level drivers are structural: Respiratory growth, initially aided by COVID, is now sustained by awareness and diagnosis work. Cardio and diabetes saw strong volume growth as products went generic and the market expanded. Neurology growth returned after execution issues were resolved, and acute therapies grew as patients who had deferred treatment returned to clinics.
Margin Walk and Cost Discipline
- Reported margin masks a one-time charge: Reported EBITDA margin of 22.3% includes a COVID inventory charge booked in materials cost. Adjusted for this, margin would have been approximately 24%, and management is tracking in line with the full-year guidance of 21% to about 22%.
- Gross margin expanded year-on-year: Reported gross margin of 63% was 165 bps above last year, driven by new launch contributions and mix change, even after absorbing the inventory charge.
- R&D investment stepped up: R&D costs rose ₹61 crore YoY, an incremental 1% of revenue, driven by ongoing clinical trials on the respiratory asset and other developmental programs. The 5.8% run rate is expected to continue for the rest of the year, and management set a long-term ceiling of 7% of revenue as specialty and biosimilar programs advance.
- Cost pressures are stabilizing: Procurement costs are seeing a trend of stabilization, and freight cost increases are being mitigated through a mix shift from air to sea and other cost-discipline measures. Forex losses on imports are partially offset by gains when reporting financials.
- Depreciation spike is transient: A sharp QoQ increase in depreciation was driven by a COVID-related impairment and will normalize from the next quarter.
Regulatory and Manufacturing Milestones
- Goa plant observations responded to: The FDA inspection in August 2022 resulted in observations, and Cipla has proactively responded. At this stage, management does not expect any material impact on planned launches for FY23.
- Abraxane timing hinges on Goa: If site approval comes through, the launch is on track for Q1 FY24 (first half of next calendar year). If approval is delayed, the launch could be pushed out by six months.
- Indore facility earns lighthouse status: The plant received a fourth industrial revolution lighthouse rating, with yields improving, cost per tablet down 15–20%, and greenhouse gas emissions reduced.
Umang Vohra: “If the Goa site approval comes, then obviously this will be in track with first quarter of the next financial year, which is the first half of the next calendar year, and if it is delayed, then it could be pushed out by six months.”
Pipeline Beyond the Near-Term Catalysts
- Peptide launches begin next fiscal: The first set of peptide product launches is expected toward the latter half of H1 FY24, adding a new complex-generic vertical to the US portfolio.
- Partner respiratory asset in FDA review: The partner has responded to FDA questions, and the asset is now in a nine-month review clock from the response date. The next inhaler asset filing is targeted for H2 of the next calendar year.
- Biosimilars and specialty are long-dated options: Biosimilar launches are expected in the 2028–2030 timeframe. On specialty, management confirmed it is “definitely an option,” with a pipeline being built between organic development and one existing asset.
- US strategy remains selective, not broad: Management does not subscribe to a breadth model of assets; the average R&D spend per asset is higher, but the strategy is about being very selective with products.
Umang Vohra: “Our strategy at least for the US is about being very selective with products, maybe the average R&D spending per asset is higher. But we don't subscribe to the breadth model of assets, where we do more projects necessarily.”
International Markets and Capital Allocation
- South Africa recovery underway: The private business demonstrated continued sequential recovery, with secondary demand strong and outperforming the market by over two times.
- Dollar-reported numbers mask local-currency strength: Reported dollar figures subsumed the adverse impact of depreciating euro, British pound, and other local currencies against the USD, which offset healthy double-digit secondary growth across DTM markets.
- ROCE tracking at the top of the range: Return on capital employed is at a healthy 20% for the trailing twelve months, in line with the commitment of a 17–20% range, and management is committing to accelerating it further.
- Cash flow timing: Q2 was a dividend-paying quarter, and US launches increased debtors; cash release is expected over Q3 and Q4.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year EBITDA margin | 21% to 22% | FY23 |
| Lanreotide market share | Reach roughly 15% share | By end of this year |
| Generic Advair launch | Launch in H2 FY23, subject to FDA review of responses | H2 FY23 |
| Abraxane launch | Q1 FY24 if Goa approved; delayed by six months if not | Q1 FY24 or H1 CY24 |
| Lenalidomide repeatability | Repeatability expected at least for this year | FY23 |
| US business base | $175–180 mn as a new base | Ongoing, barring dramatic reversal |
| Leuprolide Depo launch | Launching imminently; slow ramp like Lanreotide | Anytime now |
| R&D run rate | 5.8% of revenue | Rest of FY23 |
| Long-term R&D ceiling | Cannot exceed 7% of revenue | Long-term |
| Peptide launches | First set of launches | Latter half of H1 FY24 |
| Next inhaler asset filing | Filing targeted | H2 next calendar year |
| Biosimilar launches | Launch expected | 2028–2030 timeframe |
| ROCE | Accelerating from current 20% | Ongoing |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹5,829 cr, multi-quarter high; 6% reported growth, 12% YoY ex-COVID |
| EBITDA margin (reported) | 22.3%, 6% growth over last year; adjusted ~24% ex-COVID inventory charge |
| EBITDA (reported) | ₹1,302 cr; adjusted core operating profitability ~₹1,389 cr |
| Profit after tax | ₹789 cr, 13.5% of sales |
| Gross margin | 63%, 165 bps above last year |
| R&D spend | ₹335 cr, 5.8% of revenue; up ₹61 cr YoY |
| Employee cost | ₹951 cr, flat sequentially |
| Other expenses | ₹1,405 cr, up 12.3% sequentially, driven by higher R&D |
| Total expenses | ₹2,366 cr, up 7.2% sequentially |
| One India revenue growth (ex-COVID) | 15% YoY; reported growth 6% |
| Branded prescription growth (ex-COVID) | 15%, sixth consecutive quarter of market-beating growth |
| Consumer health annualized revenue | ₹600 cr+; overall business >20% growth YoY; transferred brands 14% growth |
| US core formulations sales | $179 million, 25% growth YoY |
| Lanreotide market share | 9.6%, up from 4.6% in Q1; tracking to ~15% by year-end |
| Albuterol market share | 16% as per IQVIA MAT Sep 2022 |
| Arformoterol market share | 38% as per IQVIA MAT Sep 2022 |
| South Africa private market share | 7.5%, third position; 7.2% growth vs market 2.8% |
| Return on capital employed | 20% for the 12-month period |
| Full year EBITDA guidance | 21% to 22% |
| US business new base guidance | $175 mn to $180 mn quarterly |